By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.

GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, ...

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Bayer’s menopause drug, Lynkuet, received a recommendation for approval from the European Medicines Agency (EMA), moving it ...

GSK plc will present new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (6 - 9 December), reinforcing its potential to redefine ...

(GLOBE NEWSWIRE) -- "Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there's no clear, consistent guidance -- ask five academic physicians and you'll get five different ...

GSK’s fair value estimate has increased from £18.07 to £18.27, indicating a minor but notable shift in analysts’ outlook for ...

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...